万孚生物(300482) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥831,629,122.23, a decrease of 68.32% compared to ¥2,625,283,985.42 in the same period last year[7] - Net profit attributable to shareholders was ¥203,678,161.27, down 77.46% from ¥903,506,781.16 year-on-year[7] - Basic and diluted earnings per share were both ¥0.46, a decline of 77.56% from ¥2.05 in the same period last year[7] - Total operating revenue for Q1 2023 was CNY 831,629,122.23, a decrease of 68.3% compared to CNY 2,625,283,985.42 in the same period last year[26] - Net profit for Q1 2023 was CNY 202,212,680.82, a decrease of 77.7% compared to CNY 901,709,729.58 in Q1 2022[29] - The total comprehensive income for Q1 2023 was CNY 202,604,008.04, significantly lower than CNY 903,678,461.03 in Q1 2022, highlighting the impact of reduced profitability[32] Cash Flow - The net cash flow from operating activities improved by 37.98%, reaching -¥221,701,390.44 compared to -¥357,477,956.88 in the previous year[7] - The net cash flow from operating activities was -221,701,390.44 CNY, an improvement from -357,477,956.88 CNY in the previous period, indicating a 38% reduction in cash outflow[37] - Total cash inflow from operating activities was 707,399,227.91 CNY, down 41.3% from 1,203,610,658.01 CNY in the previous period[37] - Cash outflow from operating activities totaled 929,100,618.35 CNY, a decrease of 40.5% compared to 1,561,088,614.89 CNY last year[37] - The net cash flow from investing activities was 11,894,625.62 CNY, a significant recovery from -252,852,743.65 CNY in the previous period[37] - Cash inflow from investing activities was 1,120,787,819.86 CNY, down 35.9% from 1,747,447,477.63 CNY in the previous period[37] - Cash outflow from investing activities was 1,108,893,194.24 CNY, a decrease of 44.7% compared to 2,000,300,221.28 CNY last year[37] - The net cash flow from financing activities was -200,348,519.87 CNY, compared to a positive cash flow of 199,910,395.91 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period were 748,525,744.53 CNY, an increase from 584,944,076.03 CNY in the previous period[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,917,755,800.57, a decrease of 6.08% from ¥6,301,138,498.06 at the end of the previous year[7] - The company's total liabilities as of Q1 2023 amounted to CNY 1,171,298,113.68, compared to CNY 1,763,580,723.22 in the previous year[28] - Total current assets decreased from CNY 3,350,388,699.00 to CNY 3,214,883,420.68, indicating a decline of approximately 4.05%[23] - Total non-current assets decreased from CNY 2,950,749,799.06 to CNY 2,702,872,379.89, reflecting a decline of about 8.38%[23] - The total assets of the company decreased from CNY 6,301,138,498.06 to CNY 5,917,755,800.57, a reduction of approximately 6.09%[23] - Short-term borrowings significantly decreased from CNY 204,357,852.72 to CNY 3,000,000.00, a decline of about 98.53%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,785, with the top ten shareholders holding a combined 33.17% of the total share capital[18] - The number of shares held by the top shareholder, Li Wenmei, is 97,843,968, representing 22.01% of the total shares[18] - The company's equity attributable to shareholders increased by 4.84% to ¥4,554,120,777.67 from ¥4,343,755,389.17 at the end of the previous year[7] - The total equity attributable to shareholders of the parent company increased to CNY 4,554,120,777.67 from CNY 4,343,755,389.17 year-on-year[28] Expenses and Income - The company reported a significant decrease in sales revenue primarily due to a reduction in antigen sales[13] - The company experienced a 58.21% reduction in selling expenses, amounting to ¥146,021,066.07 compared to ¥349,408,282.77 in the previous year[13] - Total operating costs for Q1 2023 were CNY 608,061,116.29, down from CNY 1,500,079,621.40 in the previous year, reflecting a significant reduction in expenses[29] - Research and development expenses for Q1 2023 were CNY 94,403,973.82, down from CNY 118,277,455.31 in the previous year, indicating a focus on cost management[29] - The company reported a decrease in sales expenses to CNY 146,021,066.07 from CNY 349,408,282.77 year-on-year, reflecting improved operational efficiency[29] - The company recorded other income of CNY 8,703,414.00 in Q1 2023, compared to CNY 2,095,331.29 in the same period last year, indicating potential growth in ancillary revenue streams[29] - Interest income increased by 224.51% to ¥2,529,282.86, up from ¥779,407.79 year-on-year[13] - The company received government subsidies amounting to ¥9,349,383.14, contributing positively to its financial performance[8] Inventory and Receivables - The company's inventory increased from CNY 399,967,713.19 to CNY 466,705,476.95, representing an increase of approximately 16.67%[23] - The total receivables increased from CNY 540,161,426.51 to CNY 564,452,271.95, indicating a growth of about 4.67%[23] - The company reported a total of 1,283,682,046.63 in trading financial assets at the end of the reporting period, up from CNY 938,071,800.35 at the beginning of the year[23]